美國Watson Pharmaceuticals, Inc.
2006年 制藥廠商Watson Pharmaceuticals決定以大約19億美元收購Andrx,以壯大其非專利藥(generic drug)業務,在迅速整合的產業中與較大的對手并駕齊驅。
Watson表示,上述并購將使其成為美國第三大非專利藥廠商。它將以每股25美元的價格收購Andrx,較過去30天Andrx的平均股價溢價32%。預計上述交易將增加其2007年獲利。合并后的公司將擁有超過60項非專利藥的申請。Watson表示,預計今年將推出8種或更多新藥。
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets and distributes brand and generic pharmaceutical products. With one of the broadest product offerings in the U.S. generics industry and a track record of service excellence, Watson has earned a solid reputation as a reliable and low-cost provider of quality pharmaceutical products.